Cara Therapeutics Inc

NASDAQ:CARA  
12.68
-0.31 (-2.39%)
Products

Cara Therapeutics And Vifor Pharma Announce U.S. FDA Nod For Korsuva

Published: 03/08/2021 06:08 GMT
Cara Therapeutics Inc (CARA) - Cara Therapeutics and Vifor Pharma Announce U.S. FDA Acceptance and Priority Review of NDA for Korsuva™* Injection in Hemodialysis Patients With Moderate-to-severe Pruritus.
Cara Therapeutics and Vifor Pharma Announce U.S. FDA Acceptance and Priority Review of NDA for Korsuva™* Injection in Hemodialysis Patients With Moderate-to-severe Pruritus.
FDA Has Set Prescription Drug User Fee Act (pdufa) Target Action Date of August 23.
FDA Stated That Currently It is Not Planning to Hold an Advisory Committee Meeting to Discuss Application.